Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

Integra LifeSciences Holdings (IART) has come back into focus after reporting second quarter 2026 results with a swing back to profitability, while also updating quarterly and full year revenue guidance on July 29.

The company reported second quarter sales of US$418.76 million compared with US$415.61 million a year earlier. Net income was US$4.48 million compared with a net loss of US$484.07 million in the prior year period.

Basic and diluted earnings per share from continuing operations were US$0.06. A year earlier the company reported a basic and diluted loss per share from continuing operations of US$6.31.

For the first six months of 2026, Integra LifeSciences Holdings reported sales of US$810.68 million compared with US$798.26 million a year ago. Net loss for the period was US$0.134 million, compared with a net loss of US$509.37 million a year earlier.

Alongside the results, Integra LifeSciences Holdings issued guidance for the third quarter of 2026. The company expects reported revenue between US$410 million and US$425 million, which it states would represent reported growth of 2.0% to 5.7%.

The company also adjusted its full year 2026 revenue outlook. Reported revenue is now expected in a range of US$1.654b to US$1.695b, compared with the previous range of US$1.662b to US$1.702b, with management citing the impact of a stronger US dollar on foreign exchange rates.

According to management commentary summarised on August 1, Integra LifeSciences Holdings met Wall Street revenue expectations in the second quarter and maintained its full year revenue and adjusted EPS guidance. Management also pointed to margin pressure linked to higher interest expenses and product mix, and highlighted ongoing operational execution efforts and product relaunches as areas of focus.

See our latest analysis for Integra LifeSciences Holdings.

Integra LifeSciences Holdings' latest guidance and return to profitability have come alongside a 90 day share price return of 52.05% and a year to date share price return of 38.63%, although the 3 year total shareholder return is down 62.87%. This points to improving momentum off a much weaker long term base.

If this earnings update has you thinking more broadly about medical technology and healthcare, it could be a useful moment to scan other opportunities using the 41 healthcare AI stocks. You might find companies where sentiment and fundamentals are starting to line up.

Integra LifeSciences Holdings now appears to be a healthier business than it was a year ago, yet the share price has already risen sharply. The key question for investors is whether the current valuation appropriately reflects the balance between turnaround risks and potential rewards.

Compared with Integra LifeSciences Holdings' last close at $16.65, the most followed valuation narrative points to a fair value of $27. This sets up a much more optimistic long term view than the current share price suggests.

Analysts broadly agree that Integra's Compliance Master Plan and supply chain upgrades will stabilize operations and restore revenue. However, this may actually drive a structural step change in cost efficiency and supply reliability, leading to gross margin and earnings expansion well beyond conservative estimates as operational bottlenecks are permanently resolved across legacy and newly acquired sites.

Want to see what sits behind that confidence in Integra LifeSciences Holdings? The narrative leans on a specific mix of revenue growth, margin rebuild and a future earnings multiple that is usually reserved for higher quality compounders. Curious which assumptions have to hold for $27 to make sense? The full narrative lays out the numbers.

This widely followed view uses a discount rate of 10.27% and frames Integra LifeSciences Holdings as materially undervalued relative to its projected earnings power. It rests on the idea that supply chain remediation and cost efficiency improvements can support higher margins over time while revenue trends improve off the current base.

Result: Fair Value of $27 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to watch for ongoing regulatory and quality issues, as well as pricing pressure in core products, which could quickly undermine that Integra LifeSciences Holdings optimism.

Find out about the key risks to this Integra LifeSciences Holdings narrative.

The mix of renewed optimism around Integra LifeSciences Holdings and the clear risks flagged by recent results gives you plenty to weigh up. If you want to see how those trade offs show up in the numbers and sentiment, take a closer look at the 3 key rewards and 2 important warning signs.

If Integra LifeSciences Holdings has sharpened your focus on opportunities, do not stop here. A few minutes with targeted stock lists can reveal ideas you might otherwise miss.

Spot potential value plays early by scanning 55 high quality undervalued stocks, which combines quality fundamentals with prices that may not reflect their underlying strength.

Prioritise financial resilience by checking the solid balance sheet and fundamentals stocks screener (45 results) to see companies with sturdier balance sheets and cleaner fundamentals.

Get ahead of the crowd by reviewing the screener containing 19 high quality undiscovered gems, which highlights companies that have strong metrics yet remain off most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include IART.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]